Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Smoldering Multiple Myeloma (SMM) Trials Landscape
Smoldering multiple myeloma (SMM) is an asymptomatic transitional phase between MGUS and active myeloma. Currently, most trials in China target active myeloma, while SMM trials remain focused on high-risk disease intercept.
As of 2026-09-04, there are 0 active interventional trials dedicated to this patient population in China.
Clinical Characteristics & Guidance
[Current Trial Landscape] According to current national trial snapshots, active interventional trials for low-to-intermediate risk SMM in China are limited. International and domestic guidelines recommend a "watch and wait" approach for standard-risk SMM.
[High-Risk SMM Interception] Under the Mayo 2018 "20/2/20" criteria (bone marrow plasma cells ≥20%, serum M-protein ≥20 g/L, involved/uninvolved FLC ratio ≥20), high-risk patients face ~50% 2-year progression risk. Ongoing global research explores early interceptive therapies such as lenalidomide combinations or CD38 monoclonals.
[Patient Follow-up Guidance] Patients with asymptomatic SMM should undergo rigorous 2-3 month biochemical surveillance (electrophoresis, FLC, renal panel, calcium) and annual whole-body low-dose CT or MRI imaging. Systematic therapy should only be initiated under clinical trial protocols or upon verified progression to active CRAB/SLiM criteria.
No active interventional trials specifically recruiting asymptomatic SMM in China at this time
Guidelines recommend regular surveillance for standard-risk SMM. If progression to active MM is detected, consult newly diagnosed frontline protocols.